GlassScriptPhysician profile
Maisara I Rahman
NPI 1518103472
$3,087.46
in general payments reported to CMS, 2019-2025
24 companies · $860 in 2025
The $860 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $247 · 2021: $32.61 · 2022: $540 · 2023: $484 · 2024: $638 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,982.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $729.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $426.45 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $212.61 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $204.03 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $169.52 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $166.60 | 2019-2025 | |
| Lilly USA, LLC | $147.98 | 2022-2025 | Mounjaro, Jardiance |
| Medtronic, INC. | $135.07 | 2021-2024 | Minimed 780g |
| Merck Sharp & Dohme LLC | $127.28 | 2019-2023 | Verquvo |
| Hologic Sales and Service, LLC | $120.21 | 2021-2025 | Aptima |
| Abbvie INC. | $118.69 | 2022-2023 | |
| Amgen INC. | $85.37 | 2022-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $83.95 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $75.25 | 2019-2025 | Spravato |
| Astellas Pharma US INC | $63.92 | 2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $52.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.22 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.72 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $18.05 | 2019 | |
| Therapeuticsmd, INC. | $17.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.92 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.73 | 2023 | Xifaxan |
| Cequr Corporation | $15.00 | 2024 | Cequr Simplicity |
| Takeda Pharmaceuticals U.S.A., INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maisara Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.